Davenport & Co’s BridgeBio Pharma BBIO Stock Holding History

Davenport & Co’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$283K	Buy	3,806 +506	+15%	+$35.4K	﹤0.01%	1213
2026 Q1	$245K	Hold	3,300	–	–	﹤0.01%	1206
2025 Q4	$252K	Sell	3,300 -1,500	-31%	-$98.5K	﹤0.01%	1149
2025 Q3	$249K	Hold	4,800	–	–	﹤0.01%	1133
2025 Q2	$207K	Buy	+4,800	New	+$175K	﹤0.01%	1169
2024 Q3	–	Sell	-10,200	Closed	-$258K	–	1147
2024 Q2	$258K	Sell	10,200 -100	-1%	-$2.73K	﹤0.01%	999
2024 Q1	$318K	Buy	+10,300	New	+$350K	﹤0.01%	928

Other funds holding BBIO

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

QCM

QRG Capital Management Chicago, Illinois $12.1B AUM 44.98% 1-Year Est. Return

FBT

First Bank & Trust Brookings, South Dakota $680M AUM 25.36% 1-Year Est. Return

Perpetual Ltd Sydney, New South Wales, Australia $7B AUM 19.75% 1-Year Est. Return

CPBTD

Central Pacific Bank - Trust Division Honolulu, Hawaii $984M AUM 34.19% 1-Year Est. Return

CSP

Cary Street Partners Richmond, Virginia $4.58B AUM 24% 1-Year Est. Return

Davenport & Co's BBIO Position: Q2 2026 in Review

Davenport & Co increased its BridgeBio Pharma (BBIO) stake by 15% in Q2 2026, buying an estimated $35.4K and bringing the position to 3,806 shares worth $283K. The position accounts for ﹤0.01% of the portfolio, ranked #1213.

Davenport & Co first reported a position in BBIO in Q1 2024 and has held it in 7 quarters since. The position peaked at $318K in Q1 2024. 48 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Davenport & Co held 3,806 shares of BridgeBio Pharma worth $283K as of Q2 2026.
Davenport & Co bought 506 BridgeBio Pharma shares in Q2 2026, an estimated $35.4K.
BridgeBio Pharma made up ﹤0.01% of Davenport & Co's portfolio in Q2 2026, its #1213 holding.
Davenport & Co first reported a position in BridgeBio Pharma in Q1 2024 and has held it in 7 quarters since.
Davenport & Co's BridgeBio Pharma position peaked at $318K in Q1 2024.
48 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Davenport & Co's 13F filing for Q2 2026, filed 13 Jul 2026.